ASCO

Chicago, IL—In children who are at risk for Wilms tumor, the presence of a rare genetic abnormality identifies children who can have a survival benefit from the augmentation or intensification of therapy. The abnormality—loss of heterozygosity (LOH) on chromosomes 1p and 16q (LOH 1p/16q)—is associated with worse prognosis in children with Wilms tumor.

Chicago, IL—Precision medicine in oncology is now being studied in clinical trials in oncology. These trials will pair a patient’s tumor molecular profile with drugs that address those tumor variants.

Chicago, IL—Lenvatinib (Lenvima) added to everolimus (Afinitor) extended overall survival (OS) significantly compared with everolimus alone in patients with metastatic renal-cell carcinoma (RCC). This phase 2 study also demonstrated improved progression-free survival (PFS) with lenvatinib alone and in combination with everolimus compared with everolimus alone.